AI channel feed

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

Subscribe to Endpoints News
Evan Feinberg, CEO of Genesis Therapeutics (Boris Feldman)

Genen­tech-part­nered Gen­e­sis Ther­a­peu­tics inks newest AI dis­cov­ery deal with Eli Lil­ly

A Stanford biotech rubbed elbows with Genentech in 2020, reaching a deal with the big-name biotech just over 18 months ago. And now, the AI outfit is in its second partnership with Big Pharma.

Genesis Therapeutics secured a deal with big pharma Eli Lilly, the company announced on Tuesday — to discover therapies “across a range of therapeutic areas,” according to a statement put out by the biotech.

Dean Bitan, CEO of Imagene AI (L), and Larry Ellison (Photo By Sthanlee B. Mirador)

Wait, what? Or­a­cle tech founder Lar­ry El­li­son in­vests in­to ex-stealth ge­nomics di­ag­nos­tics biotech

At last count by Bloomberg, Larry Ellison was worth close to $120 billion, putting him on the top 10 list of the richest people on the planet. And he’s shelling out a tiny bit of that to back the launch round of a buzzy diagnostic outfit in Israel.

The co-founder, ex-CEO and now CTO of tech giant Oracle Corporation co-led an $18.5 million Series A into Imagene AI, an oncology-focused biotech looking to integrate its custom algorithms into digitized genomics and predict certain aspects of someone’s cancer, such as response to certain therapies and the presence of certain mutations.

Vimal Mehta, BioXcel CEO

Psych and neu­ro R&D notch a win as BioX­cel gets FDA ap­proval for schiz­o­phre­nia, bipo­lar dis­or­der-re­lat­ed ag­i­ta­tion

While drug development for neuro and psychiatry are notoriously sluggish, the fields took a step forward Wednesday with the latest FDA approval.

BioXcel Therapeutics, a New Haven, CT biotech, announced the approval early Wednesday for its lead program dexmedetomidine, a sublingual film taken orally. The drug, which will be known as Igalmi, is indicated to treat agitation associated with schizophrenia and bipolar I or II disorder and is the company’s first drug to get past the FDA finish line.

Andrew Beck, PathAI CEO and co-founder

Glax­o­SmithK­line keeps truck­ing along­side AI with new, mul­ti-year pathol­o­gy part­ner­ship with Boston out­fit

Big Pharma has been in hot pursuit of the allure of AI integration, with the alleged potential for revolutionizing drug R&D. The UK’s GlaxoSmithKline has been no exception, with its partnerships in the past with King’s College for personalized oncology treatments and with Cerebras for access to its superAI platform.

Introduce Boston AI biotech PathAI. After already aligning arms with Bristol Myers Squibb, the six-year-old startup is linking up with GSK. It’s a big get for PathAI, which closed a Series B in 2019, bagging $75 million in the process and, two years later, $165 million in a Series C.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.

Jeff Elton, ConcertAI CEO (via MassBio)

Con­cer­tAI sings a uni­corn tune as the FDA-part­nered clin­i­cal tri­als soft­ware up­start ex­pands

The crescendo is building at ConcertAI as the artificial intelligence life sciences startup reels in its ensemble to boost clinical study diversity, expand decentralized clinical trials and pile on the real-world data for cancer treatments.

The FDA-partnered upstart raised a $150 million Series C, soaring into unicorn status to a $1.9 billion valuation, to take its tech on a worldwide tour. The current set list of 45 biopharma and contract research organization customers is not enough for the five-year-old Cambridge, MA, company.

Chris Hart, Creyon Bio CEO

An AI biotech emerges from stealth promis­ing drugs 'on de­mand.' What will that look like, and is it even pos­si­ble?

The newest AI and machine learning biotech launched Tuesday morning, and it’s promising some big things. But can the company deliver?

Creyon Bio emerged from stealth with $40 million in seed and Series A financing, the company said, with the goal of delivering precision medicines “on demand” once its platform is fully realized. The biotech wants to focus on both rare and common diseases, though it’s not specifying which ones, and develop oligonucleotide-based medicines that can work with any modality, be it antisense, siRNA or DNA and RNA editing.

Bio­phar­ma has hyped AI for years. But as the first tri­als get un­der­way, ex­perts try to man­age ex­pec­ta­tions

If you’re at all familiar with the biotech space, you’ve probably heard of the promises of artificial intelligence and machine learning.

These promises have been tantalizing. AI and ML can, proponents claim, help researchers speed along the arduous and expensive drug development process. By attempting to utilize algorithms and computing power so dynamic as to essentially eliminate menial tasks and trial and error altogether, the technology comes with big expectations likening it to a new industrial revolution.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jacob Berlin (L) and Eli Berlin (Terray Therapeutics)

AI start­up grabs $60M, un­veils plat­form aimed at drug dis­cov­ery's 'da­ta prob­lem'

As the computational tools for drug discovery proliferate, it can start to feel like an artificial intelligence or machine learning player is entering the fray every other week. But no matter how sophisticated those algorithms are, something could still be missing.

That’s according to Terray Therapeutics, which is joining the party with $60 million after three years in stealth mode and bringing with it not just software but hardware that it describes as a chemistry engine operating at massive scale.

Jong Lee, Day Zero CEO (via Day Zero website)

Ge­nomics + ma­chine learn­ing = com­pa­ny's strat­e­gy to speed up hos­pi­tal di­ag­nos­tics and iden­ti­fy an­tibi­ot­ic re­sis­tance

Day Zero Diagnostics has been focused on combining genome sequencing and machine learning to diagnose infectious diseases. And now the diagnostics player has netted its biggest financing round yet.

Company execs announced earlier this week that the biotech netted $21 million in a venture equity financing round lead by Sands Capital. Other investors tagged on as well, including the backing of big med-tech company BD (Becton, Dickinson and Company) and Hongkou Capital as new investors.

Christopher Trummer, CelerisTx CEO

Mer­ck KGaA en­lists lit­tle AI play­er on pro­tein de­grad­er dis­cov­ery

Merck KGaA would like to come up with some protein degraders — the fashionable way.

The German pharma has tapped CelerisTx, a Menlo Park, CA-based biotech with roots in Austria, and its artificial intelligence platform for two drug discovery projects. The main goal, according to the companies, is to identify active small molecule binders.

Founded against the backdrop of emerging PROTACs and molecular glues, CelerisTx’s mission is to fill the gap for a rational approach to designing these compounds, which typically consists of two sides — one binding to the target protein, another to the E3 ligase — and a linker to pull them together.